NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
In this article:
NewAmsterdam said Monday its experimental drug lowered "bad" LDL cholesterol But the results were below biotech stock analysts' views.
Advertisement